Key Players
Competitive Landscape
Four kinds of supplier compete in the abuse deterrent formulations market: branded opioid manufacturers, formulation-platform developers, prodrug specialists and long-acting depot companies.
Capital has moved in two directions since 2025: continuity for marketed abuse-deterrent opioids and late-stage prodrug programs that add overdose protection. Knoa Pharma began operations in May 2026 and assumed medicines formerly distributed by Purdue Pharma. Ensysce Biosciences reached 50% of interim enrollment for its PF614 Phase 3 trial in January 2026. Price remains relevant during formulary review, although formulary committees compare suppliers on label evidence plus release reliability and monitoring burden.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| Knoa Pharma began operations in May 2026 and assumed distribution of medicines formerly supplied by Purdue Pharma. | Health systems need continuity for established medicines under tighter diversion oversight and public-health governance requirements. | Purpose-bound ownership separates opioid portfolio continuity from the predecessor company that originally marketed those products. | Revenue remains available through continued supply of established medicines under distribution controls and public-health governance requirements. |
| Ensysce Biosciences reached 50% of interim enrollment for the PF614 Phase 3 trial in January 2026 across three United States sites. | Pain specialists need analgesia that adds abuse protection without sacrificing predictable relief during ordinary dosing. | Prodrug programs have progressed from formulation research into pivotal studies that test clinical performance at commercial scale. | Licensing revenue could develop in severe acute-pain settings that require controlled short-duration treatment and product-specific abuse protection. |
| Collegium Pharmaceutical reported USD 199.3 million in 2025 Xtampza ER net revenue during February 2026 full-year reporting. | Formulary committees need current commercial evidence to maintain differentiated coverage for an abuse-deterrent medicine against conventional products. | Marketed extended-release products retain value through established prescribing pathways even as new platforms enter clinical development. | Established products can generate revenue through qualified chronic-pain use and evidence-led formulary retention in regulated health systems. |
Protega Pharmaceuticals, Camurus, Acura Pharmaceuticals, Teva Pharmaceutical Industries and Pfizer compete through formulation evidence or delivery depth without an additional dated development appearing for them in this section.
Source: Future Market Insights, Abuse Deterrent Formulations Market and Opioid Analgesics Market Reports, 2026-2036.
Collegium Pharmaceutical covers current extended-release oral products through a marketed portfolio, while Protega adds immediate-release deterrence through RoxyBond. Knoa Pharma maintains distribution of established opioid analgesics and Ensysce Biosciences extends competition into prodrug and overdose-limiting chemistry.
Who leads the abuse deterrent formulations market?
Collegium Pharmaceutical leads the profiled group on disclosed product revenue after February 2026 reporting confirmed Xtampza ER retained a documented 2025 revenue base. Knoa Pharma competes through an inherited opioid analgesic portfolio governed by a public-health ownership structure that began operations in May 2026.
Which suppliers have documented abuse-deterrent labeling?
FDA currently lists products supplied by Collegium Pharmaceutical, Knoa Pharma and Protega Pharmaceuticals with labeling describing abuse-deterrent properties. Teva Pharmaceutical Industries and Pfizer retain documented historical labeling through Vantrela ER and Embeda under different formulation mechanisms.
Which companies provide oral abuse-deterrent products?
Protega Pharmaceuticals supplies the immediate-release RoxyBond formulation across several approved oxycodone strengths for severe pain treatment. Ensysce Biosciences develops the PF614 prodrug platform, while Acura Pharmaceuticals advances LIMITx candidates intended to limit exposure following excess oral administration.
Which suppliers serve the United States and Europe?
Collegium Pharmaceutical, Knoa Pharma and Protega Pharmaceuticals have verified United States positions in oral opioid formulations. Camurus serves Europe and the United States through Buvidal and Brixadi, while other profiled platform developers currently show narrower verified regional coverage.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| Collegium Pharmaceutical | United States | Xtampza ER provides current extended-release abuse-deterrent labeling and maintains a marketed commercial position in the United States. |
| Knoa Pharma | United States | Knoa Pharma distributes inherited opioid analgesics through an independent public-health governance model that began operations in the United States during May 2026. |
| Protega Pharmaceuticals | United States | RoxyBond provides immediate-release oxycodone with current abuse-deterrent labeling under SentryBond formulation technology in the United States. |
| Acura Pharmaceuticals | United States development platform | AVERSION and LIMITx address manipulation or excess oral administration, although current development remains dependent on licensed funding. |
| Teva Pharmaceutical Industries | United States historical approval | Vantrela ER received FDA approval in January 2017 with documented oral, intranasal and intravenous deterrence data. |
| Pfizer | United States historical approval | Embeda received updated abuse-deterrent labeling in October 2014 through a morphine and naltrexone combination mechanism. |
| Camurus | Europe, Australia and United States | Buvidal and Brixadi provide weekly or monthly buprenorphine depots through direct commercialization and licensing routes. |
| Ensysce Biosciences | United States development stage | PF614 uses TAAP prodrug chemistry, while PF614-MPAR adds an overdose-protection mechanism for severe pain programs. |
Research Methodology
The companies here show how the market is structured and should not be read as a ranking. Inclusion requires current and verifiable evidence that a company supplies abuse-deterrent formulations for pain treatment or closely related opioid-dependence uses. Evidence comes from official company websites and filings, with regulator records supporting product status and dated corporate announcements. Regulatory status belongs to the product and legal entity that holds it, not the wider corporate group. Technology shares are FMI estimates, with the 41.0% physical and mechanical barrier figure applying to 2026.
